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Abstract
Introduction Monoamine-based antidepressants inhibit neu-
rotransmitter reuptake within short time. However, it
commonly takes several weeks until clinical symptoms
start to resolve—indicating the involvement of effects
distant from reuptake inhibition.
Objective To unravel other mechanisms involved in drug
action, a “reverse” pharmacological approach was applied
to determine antidepressant-induced alterations of hippo-
campal gene expression.
Materials and methods The behavioral response to long-
term paroxetine administration of male DBA/2Ola mice
was assessed by the forced swim test (FST), the modified
hole board (mHB), and the dark/light box. Hippocampi of
test-naive mice were dissected, and changes in gene
expression by paroxetine treatment were investigated by
means of microarray technology.
Results and discussion Robust effects of paroxetine on
passive stress-coping behavior in the FST were observed.
Furthermore, anxiolytic properties of long-term antidepres-
sant treatment could be identified in DBA mice in both, the
mHB and dark/light box. Analysis of microarray results
revealed a list of 60 genes differentially regulated by
chronic paroxetine treatment. Preproenkephalin 1 and
inhibin beta-A showed the highest level of transcriptional
change. Furthermore, a number of candidates involved in
neuroplasticity/neurogenesis emerged (e.g., Bdnf, Gfap,
Vim, Sox11, Egr1, Stat3). Seven selected candidates were
confirmed by in situ hybridization. Additional immunoflu-
orescence colocalization studies of GFAP and vimentin
showed more positive cells to be detected in long-term
paroxetine-treated DBA mice.
Conclusion Candidate genes identified in the current study
using a mouse strain validated for its responsiveness to
long-term paroxetine treatment add, in our opinion, to
unraveling the mechanism of action of paroxetine as a
representative for SSRIs.
Keywords Antidepressant . Behavior . Hippocampus .
Microarray . Neurogenesis . Neuroplasiticity
Introduction
Monoamine-based antidepressants enhance neurotransmis-
sion by various mechanisms within a short time, while
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resolution of depressive symptomatology takes several
weeks, sometimes months. This discrepancy in time
course suggests that the well-characterized initial mecha-
nisms trigger a number of adaptive responses that finally
allow for incremental improvements of psychopathology.
For example, under naturalistic clinical conditions, only
about 35% of depressed patients achieve full clinical
remission within 8−12 weeks of treatment with citalo-
pram, a selective serotonin reuptake inhibitor (Trivedi
et al. 2006). Even after sequential treatments with
alternatives, including augmentation strategies, a consid-
erable percentage of the patients fail to remit (Fava and
Davidson 1996; Carvalho et al. 2007). Apparently, the
various antidepressants induce cellular mechanisms beyond
monoamine receptors, and successive time-consuming
changes in neuronal and glial circuitries determine the
clinical effects of an antidepressant medication (Nestler
et al. 2002). Over the last years, the search for novel
antidepressants that act more focused followed two
complementary strategies: (1) accumulated neuroscience
findings were translated into focused targets, e.g., the well
founded stress-hormone (glucocorticoids, corticotrophin-
releasing hormone CRH) excess among depressive patients
was translated into drugs that block glucocorticoid and
CRH receptors (Holsboer and Ising 2008); and (2)
unbiased approaches were employed where human genetic
studies contrasting depressed patients with healthy con-
trols identified genetic variations that, when associated
with gain or loss of gene function, may serve as novel
targets (Craddock and Forty 2006).
The latter approach emerged from decoding the human
genome and was long considered to be the gateway to
personalized medicine where patients are treated according
to their genetic makeup. Some interesting novel drug
targets came up by these strategies (e.g. Lucae et al. 2006;
McQuilin et al. 2008), but overall, the success in using
genotype information for identification of valid drug
targets is limited so far. The main reason for this
disenchantment is that the genotype provides little infor-
mation about changes in gene activity following a cellular
challenge. Environmental factors ranging from early
childhood trauma to previous diseases, drug exposure,
acute life events, or nutrition, may all impact upon
signal-induced changes in gene activity. Such epigenetic
modulations can be reversible, enduring, or even trans-
generational (e.g., Tsankova et al. 2007; Mill and
Petronis 2007). The introduction of microarrays, a tech-
nique that profiles levels of many thousand mRNA
transcripts, was embraced because mRNA expression
levels are influenced by both, genetic polymorphisms
and environmental factors. A major drawback for studies
of human depression is the inaccessibility of diseased
tissue and the limitation imposed on extrapolations from
expression profiles in peripheral cells (e.g., lymphocytes)
to neurons or glial cells in defined brain areas (Sullivan
et al. 2006). Therefore, gene expression profiles relied on
post mortem studies where defined brain areas of affected
individuals were contrasted with those of non-affected
controls (e.g., Mirnics et al. 2001; Sequeira et al. 2007).
Studies interrogating the effects of drugs on gene activity
in selected brain areas cannot use such a strategy because
the effects of a given drug and the underlying disease
cannot be differentiated with certainty. Therefore, studies
aiming at discovery of genes that are regulated by
antidepressants mainly rely on rodent brains (e.g., Conti
et al. 2007; Nakatani et al. 2004; Wong and Licinio 2004;
Yamada et al. 2005), as genetically homogenous animals
can be used, and most confounding factors can be
controlled.
Validation of genes emerging from microarray analysis is
a major challenge and might benefit from the generation or
the use of already existing knockout models. Despite this
fact, pharmacogenomic studies rarely have been conducted
in mice. In the current study, we used a DBA/2Ola (DBA/2)
mouse line as we hypothesized that antidepressant-induced
changes in gene expression are more relevant if (1) the
animal model exhibits already a phenotype resembling
some signs and symptoms of the human disease, and (2)
these features are responsive to the kind of drugs under
study. The chosen DBA/2 strain of mice shows a high level
of anxiety-like behavior (Yilmazer-Hanke et al. 2003; Ohl
et al. 2003). Anxiolytic properties of chronic antidepressant
treatment have been reported in mice (Mirza et al. 2007)
and human patients (Pillay and Stein 2007). Furthermore,
the DBA/2Ola mice display a reduced inhibitory HPA
axis feedback compared to another inbred mouse strain
(Thoeringer et al. 2007). This neuroendocrine impairment is
a characteristic feature among patients with depression (for
review see Holsboer 2001).
The present microarray analysis focused on the
hippocampus, a brain area implicated in the neuropa-
thology and psychopathology of affective disorders
(Campbell and Macqueen 2004; Engin and Treit 2007).
Moreover, the hippocampus displays morphological alter-
ations in depressed patients that can be influenced by
antidepressant treatment (Duman and Monteggia 2006).
We treated DBA/2 mice with paroxetine or vehicle by oral
application and examined paroxetine-induced behavioral
changes in parallel with changes of hippocampal gene
expression. Seven candidate genes that emerged from the
microarray experiment were chosen and confirmed by in
situ hybridization. Finally, we used immunofluorescence
colocalization studies to support that some of the parox-
etine-induced changes in gene activity affect genes that are
involved in neurogenesis and supposedly also in neuronal
plasticity.
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Materials and methods
Subjects
Male DBA/2OlaHsd mice (Harlan Winkelmann, Germany)
aged 8−9 weeks at arrival were kept under standard
laboratory conditions (21±2°C, 45−55% humidity, 12:12 h
light cycle, with lights on at 7:00 A.M.) with food and water
available ad libitum. The animals were housed singly in
standard cages (30×20×14 cm), and treatment started after a
habituation period of 2 weeks after arrival. Animal experi-
ments were performed in accordance with the NIH Guide for
the Care and Use of Mammals in Neuroscience and
Behavioural Research and the Guide for the Care and Use
of Laboratory Animals of the Government of Bavaria,
Germany.
Treatment
Animals were randomly distributed to the treatment group
vehicle or paroxetine (10 mg/kg). Paroxetine was prepared
freshly before treatment by diluting it in tap water (1 mg/ml),
and before each application, the preparation was thoroughly
mixed. Drug or vehicle was given orally by gavaging twice
per day, i.e., in the morning between 9:00 and 10:00 and in
the afternoon between 6:00 and 7:00 P.M., over a treatment
period of 28 days. On day 29, the animals were treated in
the morning, and depending on their assignment to the
various experimental groups, behavioral tests were per-
formed. Subsequent to testing, animals were euthanized by
an overdose of isofluran, and the brains were taken. The
brains of test-naïve mice were processed for microarray
experiments or in situ hybridization /immunohistochemistry.
Behavioral testing
Analysis of behavioral effects of the chronic paroxetine
application was done in different experimental groups (1−3,
see below) of test-naïve animals. The forced swim test
(FST) was applied, as it is a commonly used test to assess
antidepressant-like properties of compounds (Cryan and
Holmes 2005; Porsolt et al. 1977). We used the modified
hole board test (mHB) in order to obtain a comprehensive
overview on behavioral changes under mild stressful
conditions. The dark/light box was used to specifically
address drug-induced changes in anxiety-like behavior.
The FST and testing in the dark/light box were
performed 4 h after last application in order to confirm
the behavioral effects of the treatment at the same time
point when the brains of test-naïve-treated mice were
taken for microarray analysis. The mHB was performed
30 min after last application as many published results
on behavioral effects of antidepressants were assessed at
this time point (e.g., Lucki et al. 2001; David et al. 2003;
Crowley et al. 2005).
During the 5-min test periods, behavior of the animals
was recorded by means of a video camera, and a trained
observer directly scored the respective parameters. Data
were statistically analysed by Mann–Whitney U tests.
Experimental group 1 (FST)
FST1 was performed on day 29 of treatment (12:30−2:00
P.M.), 4 h after the oral treatment with either vehicle (n=7)
or paroxetine (n=7). Each animal was placed into a beaker
(diameter 12 cm, height 24 cm) filled with water
(temperature 25−26°C) to a height of 12 cm for a test
period of 5 min. The parameters struggling (vigorous
attempts to escape), swimming, and floating (immobile
position with only small movements to keep balance) were
scored by a trained observer blind to the treatment. As we
were interested in the effects of a first FST exposure on the
stress-coping strategy, all animals were retested the next
day (24 h after the FST1). Animals received either vehicle
or paroxetine at the evening of day 29 and in the morning
of day 30, 4 h before they were exposed to the second FST.
Experimental group 2 (mHB)
The mHB (for details, see Ohl et al. 2001) was performed
on treatment day 29 (9:30–11:20 a.m.), 30 min after oral
treatment with vehicle (n=7) or paroxetine (n=5, as two
animals of the paroxetine group were stopped to be treated
after they showed a bodyweight loss of around 20% at
weeks 3–4). The day before the experiment, each animal
received three oak flakes for habituation as an oak flake
was used as familiar food in the test; a piece of almond
represented the novel food and was placed together with the
oak flake in one corner of the test apparatus. The animals
were placed into the outer area of the test apparatus, facing
the board. During the 5-min test period, the following
behaviors were scored: line crossings, stretched attends,
rearing, self-grooming, board visits, hole exploration,
exploration and intake of familiar and novel food, and
defecation.
Experimental group 3 (dark/light box)
Testing in the dark/light box was performed on treatment
day 29 (12:30−2:00 P.M.), 4 h after oral application of
vehicle (n=7) or paroxetine (n=7). Each animal was placed
in the dark compartment (15×20×25 cm) of the test
apparatus, facing the tunnel (4×7×10 cm) connecting the
dark to the brightly lit (680–700 lx, 30×20×25 cm)
compartment (for details see Timpl et al. 1998). During
the 5-min test period, the time spent in each compartment
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(dark, tunnel, and lit), the latency until the first full entry
(with four paws), and the number of full entries into the lit
compartment were assessed.
Brain area dissection and RNA isolation
Experimental group 4
Animals were treated with either vehicle (n=10) or
paroxetine (n=10) in parallel to the animals of experimental
group 1 (FST), and 4 h after the last oral treatment, the
animals were euthanized by an overdose of isofluran. The
brains were removed, and five brains of each treatment
were immediately frozen and stored at −80°C until
sectioning for validation purpose (in situ hybridization or
immunohistochemistry, see below). The hippocampi of the
remaining five brains of each treatment were dissected,
weighed, and immediately processed.
Total RNA was extracted with 300 µl of TRIzol reagent
(Invitrogen, Carlsbad, CA, USA). The tissue was homog-
enized by using a pipette, 1 µl linear Acrylamid (Ambion,
Huntington, UK), and 60 µl chloroform (Merck, Darmstadt,
Germany) was added to the homogenate which subsequently
was centrifuged for 5 min at 13,000 rpm. The aqueous
phase was decanted, and an equal volume of isopropanol
(∼180 µl) was added to this aliquot. The mixture was
allowed to precipitate for 30 min at −80°C. The precipitate
was collected by centrifugation at 13,000 rpm for 30 min.
The pellet was washed with ethanol (70%), briefly
centrifuged, air dried, and afterwards resuspended in 11 µl
Ampuwa water (Fresenius, Bad Homburg, Germany).
Gene expression profiling
Total RNA obtained from hippocampi of individuals of the
treatment groups vehicle (n=5) and paroxetine (n=5) was
apportioned and used on three different microarray plat-
forms (Affymetrix, Codelink, MPIP) to analyze treatment-
induced changes in gene expression in hippocampi of
DBA/2 mice.
Affymetrix mouse MOE430A GeneChips (oligonucleotide-
based) and Codelink Mouse Uniset I BioArrays (oligonu-
cleotide-based) were purchased from the manufacturer.
In-house mouse cDNA-based microarrays were printed
with the Chipwriter Pro (Biorad) on Corning GAPS II
glass slides using BMAP (brain mouse anatomy project)
and MMSV (Mus musculus sequence verified) libraries
(Research Genetics) as well as 6,000 cDNA clones obtained
from the RZPD resource center (http://www.rzpd.de).
Additional control and reference cDNAs were included
resulting in a total of 19,048 cDNAs representing 12,847
unique unigene clusters (based on unigene build no. 150).
Using Unigene annotation, we found a total of 4,862 genes
represented on all three platforms.
For the MPIP microarrays, all bacterial clones were
amplified by polymerase chain reaction (PCR), purified,
and verified by gel electrophoresis. The spotting buffer
contained 3× standard saline citrate (SSC) and 1.5 M
Betaine. After spotting, the arrays where heated to 80°C for
10 s and crosslinked using a UV Stratalinker 2400 at 60 mJ
(Stratagene). Before blocking, the slides were dried at 65°C
for 30 min. Immediately after this, the slides were
incubated in blocking solution (50% Formamide, 5× SSC,
0.1% sodium dodecyl sulfate (SDS), 0.1 mg/ml bovine
serum albumin) at 42°C for 1 h. The blocking was followed
by shortly shaking the slides in H2O, then in isopropanol.
The arrays were dried by centrifugation and stored at room
temperature.
Probe construction, microarray hyridization, and data
acquisition
For the Affymetrix GeneChips, 10 µg of total RNA of each
individual were amplified and labeled using the Megascript
T7 kit (Ambion). For each animal of the vehicle (n=5) or
paroxetine (n=5) group, 5 µg of the biotin-labeled
fragmented aRNA were hybridized to a single MOE430A
GeneChip. Subsequent steps were performed according to
the manufacturer’s protocol.
Correspondingly, ten BioArrays from Codelink were
hybridized with non-pooled biotin-labeled aRNA obtained
by amplification of 5 µg total RNA per mouse using the
manufacturer’s protocols and reagents.
The cDNA microarray (MPIP) experiment was per-
formed on group-wise pooled material, using dual color
(Cy3/Cy5) design with direct sample comparison of
indirectly labeled aRNA, including dye swapping. For this,
2 µg of total RNA of each individual were amplified,
labeled and cleaned-up using Ambion’s MessageAmp
Aminoallyl mRNA amplification and labeling kit and
Amersham’s Cy3 and Cy5 monoreactive dyes. Ten cDNA
microarrays were hybridized with pools of aRNA from
experimental and control animals, respectively. Hybridiza-
tion was carried out for 16 h at 50°C under a coverslip
using 5 µg of labeled aRNA per dye and a hybe buffer
containing 50% Formamide, 5× SSC, 0.1% SDS, 0.1 mg/ml
mouse COT1-DNA, and 5 µg Poly(dA) per array. Slides
were washed for 5 min at 42°C with 2× SSC/0,1% SDS,
followed by a wash at RTwith 0.1× SSC/0.1% SDS for 10min
and a third washing step at RT with 0.1× SSC for 1 min.
The arrays were rinsed in 0.01× SSC for up to 10 s and dried
by centrifugation. Fluorescent array images were acquired
using a ScanArray 4000 scanner (Perkin Elmer; ScanArray
Version 3.1) with 87% Laser power (Cy3), 70% Laser power
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(Cy5), and PMT gain 80% (Cy3, Cy5). Data were quantified
using Quantarray Software (Perkin Elmer; Version 2.1.0.0)
with fixed circle mode and transferred into a PostgreSQL
database for further processing. Following identification of
significantly regulated genes, the respective spots on the arrays
were visually inspected (see Supplementary Table S1).
Data analysis
Affymetrix data were analyzed using the DNA-Chip
Analyzer Software (dCHIP, Version: Sep 15, 2005) which
is suitable for analysis of multiple GeneChips (Li and Wong
2001; http://www.dCHIP.org). Using outlier images, one
chip (vehicle treated) was identified as problematic and was
therefore removed from further analysis. The following
criteria for detection of differentially expressed genes were
chosen: perfect match only model, no log transformation,
Experiment/Baseline>1.35 or Baseline/Experiment>1.35;
Present call percent of Baseline≥75; Present call percent of
Experiment≥75; p value≤0.02; not using the lower 90%
confidence bound of fold-change criterium. The p value
was chosen in a way that the false discovery rate (FDR),
calculated using 1,000 permutations, constituted 12.5%.
Codelink data were normalized by median centring using
Amersham’s analysis software. Further analysis was per-
formed using Significance Analysis of Microarrays (SAM,
Version 2.10; Tusher et al. 2001). For this, present/absent calls
were generated analogous to the Affymetrix system. A feature
was assigned “present”, if quality was “good” and above_thr
was “true”; all other features were assigned “absent”. The
following settings were chosen for the analysis: response
type: 2 class, unpaired; unlogged data; using T statistic;
median centring; 1,000 permutations; automatic s0 factor
estimation; delta: 1.0; false discovery rate: 12.13; Present call
percent of Baseline≥75; Present call percent of Experiment≥
75; with no fold change hurdle (see Larsson et al. 2005).
Using an additional absolute fold change threshold of 1.35,
16 genes could be detected as differentially expressed.
Raw data from MPIP cDNA microarrays were normal-
ized according to the procedure outlined in Yang et al.
(2002) and subjected to a t test for detection of differential
expression. The obtained p values were corrected for
multiple testing using Benjamini–Hochberg’s FDR procedure
(Benjamini and Hochberg 1995). Genes were considered as
differentially expressed when the FDR was <0.1, and the
absolute fold change was >1.35.
In situ hybridization
Radioactive in situ hybridization experiments were per-
formed according to standard protocols (Droste et al. 2003).
Probes were generated using templates created by PCR from
sequence verified clones of the microarray cDNA library
(Penk1: M13227; Bdnf: AI854196; Gfap: AI836096; Sox11:
AI836553; Vim: AI845820; Calb1: AI452326; Tex261:
AI843892). Tissue slices of corresponding brain areas from
vehicle and antidepressant-treated animals were positioned
on the same slide to ensure identical processing conditions.
Immunohistochemistry
Colocalization studies of GFAP and vimentin were performed
on 4% paraformaldehyde-fixed tissue sections prepared from
frozen mouse brains using the primary antibodies rabbit-anti-
GFAP (1:250, #Z0334, DakoCytomation) and mouse-anti-
VIM (1:50, #V5255, Sigma). Secondary antibodies used were
Alexa Fluor 488 goat-anti-rabbit (1:500, Molecular Probes)
and biotinylated goat-anti-mouse IgG (1:300, VectorLabs
#BA-9200) in combination with Texas Red Avidin D (1:60)
from Vector Fluorescent Avidin Kit (VectorLabs #A-1100).




Mice treated chronically with paroxetine compared to
vehicle-treated mice showed a significant reduction in time
floating (FST1: p=0.001; FST2: p=0.004). Time Strug-
gling was increased by paroxetine but did not reach the
significance level (FST1: p=0.2; FST2: p=0.16), and time
swimming was slightly enhanced in FST1 (p=0.2) and
significantly enhanced in FST2 (p=0.001; Fig. 1).
A second exposure to the FST induced an increase in
passive floating behavior in both treatment groups, but a
significant change was only observed in the animals treated
with vehicle (comparison time floating FST1 to FST2
within vehicle group: p=0.01).
Modified hole board
In the mHB test, parameters indicating general activity/
exploration were not affected by the chronic paroxetine
treatment (line crossings: p=0.4, number of rearings: p=
0.6). The paroxetine group showed a significant reduction
in risk assessment behavior, i.e., the number of stretched
attends was lower (p=0.04). The animals showed a trend to
spend more time in the exposed area (percent time on
board: p=0.1); the latency until first entry on board was
only slightly reduced (p=0.2). The latencies for the intake
of familiar or novel food were decreased but did not reach
significance level (p=0.1; p=0.06). Furthermore, the
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latency until the animals showed grooming behavior and
the number of boli were nonsignificantly reduced in the
paroxetine group (Fig. 2).
Dark/light box
Changes in anxiety-like behavior observed in the mHB test
could be confirmed by use of a more specific anxiety test,
the dark/light box. Animals chronically treated with
paroxetine made significantly more entries into the lit
compartment of the apparatus (percent entries: p=0.012),
spent more time in it (percent time: p=0.014), and the
latency until the first entry was lower (p=0.01). Further-
more, it was observed that paroxetine-treated animals spent
more time in the connecting tunnel between the dark and lit
compartment (p=0.004), and they displayed an overall
increase in the number of entries into either the dark or the
lit compartment (p=0.005), the latter is interpreted as a
result of behavioral disinhibition (Fig. 3).
Microarray results
According to the criteria selected for the analysis of the data
and the detection of significant gene regulation (see
“Materials and methods” section) by the chronic treatment,
a total of 60 genes was detected (Table 1).
By using Affymetrix Genechips and the appropriate
analysis, 28 genes were discovered as differentially
expressed in mice chronically treated with paroxetine (18















































































































Fig. 2 Behavioral effects of chronic paroxetine treatment in DBA/2Ola mice assessed by the modified hole board on day 29 of treatment, 30 min















































































































Fig. 1 Behavioral effects of chronic paroxetine treatment in DBA/
2Ola mice assessed by the forced swim test (FST1, a) on day 29 of
treatment, 4 h after last application. The second FST (FST2, b) was
performed 24 h after FST1 and 4 h after application of paroxetine.
(grey bars: vehicle, n=7; black bars: paroxetine 10 mg/kg, twice per
day, n=7), *p<0.05
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genes could be detected as differentially expressed (six up-,
ten down-regulated) and by means of the MPIP platform,
27 genes were found to be differentially expressed (21 up-,
six down-regulated). In 28 cases, the significant regulation
on one platform was supported by a comparable fold
change on at least one more platform. Of these, 11 genes
also matched the chosen significance criteria on a second
platform. Fourteen significantly regulated genes were only
represented on one of the platforms, and in 18 cases, probes
for a gene were present on at least two platforms but did not
show a comparable fold-change. This finding could be
explained by methodological or analytical differences or by
a platform-dependent probe bias.
Significantly regulated candidates and the absolute fold
change detected are listed in Table 1; additional annota-
tional data and information on respective p values and
standard errors are given in Supplementary Table S1.
Based on Gene Ontology information, the various gene
candidates were assigned to different functional groups,
whereby it has to be mentioned that for the product of
several genes, a variety of functions were attributed by
Gene Ontology.
Validation of selected genes by in situ hybridization
and immunohistochemistry
Seven candidates were selected due to different levels of up-
or down-regulation in the different Microarray platforms
(Affymetrix, Codelink, MPIP): Penk1 (preproenkephalin 1,
threefold up-regulated, Affymetrix), Bdnf (brain-derived
neurotrophic factor, 2.1-fold up-regulated, MPIP), Gfap
(glial fibrillary acidic protein, 2.2-fold up-regulated, Affyme-
trix), Sox11 (SRY-box containing gene 11, 1.9-fold up-
regulated, MPIP), Vim (vimentin, twofold up-regulated,
Affymetrix and 2.3-fold up-regulated, MPIP), Calb1
(calbindin-28 K, 1.5-fold down-regulated, Affymetrix and
Codelink), and Tex261 (testis expressed gene 261, 1.4-fold
down-regulated, MPIP). Verification of the expression level
of each candidate in hippocampus slices of four control and
four paroxetine treated animals by in situ hybridization
confirmed the microarray results, and representative pictures
for each comparison are shown in Fig. 4.
The colocalization study on the protein products of Gfap
and Vim (Fig. 5) in the hippocampus (eight slices per
individual) of vehicle and paroxetine-treated mice (n=5 per
group) confirmed that the transcriptional changes detected
were also reflected on the protein level. Furthermore,
analysis of the cells positive for both immunofluorescence
signals (Fig. 5a,b) revealed for each of the paroxetine-
treated mouse a higher number of cells (Fig. 5c) co-
expressing GFAP and vimentin in the dentate gyrus.
Discussion
Using three different behavioral tests, we corroborated that
chronic paroxetine treatment of DBA/2 mice, that show an
anxiety-like phenotype at baseline, induces behavioral
changes consistent with an antidepressant-like profile. In
the FST, the animals showed a paroxetine-induced decrease
in passive behavior, which is in agreement with previous
reports demonstrating that monoamine-based antidepres-
sants induce such behavioral changes (for review see
Jacobson and Cryan 2007). In addition, anxiolytic effects
have been shown in two independent behavioral tests, the
mHB and the dark/light box. In the only mildly aversive
mHB test, risk assessment behavior as well as the overall
pattern of avoidance behavior was reduced after application
of paroxetine—indicating an anxiolytic effect of this
treatment (Blanchard et al. 1993; Ohl et al. 2001). In the
dark/light box, a commonly used specific anxiety test















































































Fig. 3 Behavioral effects of
chronic oral paroxetine treat-
ment in DBA/2Ola mice
assessed by the dark/light box
on day 29 of treatment, 4 h min
after last application (grey bars:
vehicle, n=7; black bars:
paroxetine 10 mg/kg, twice per
day, n=7), *p<0.05
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Table 1 Transcripts, of which the expression is significantly changed by chronic antidepressant treatment in at least one platform, grouped by
functional classification according to Gene Ontology (GO)
Gene symbol Gene name Affy Code MPIP
Calcium binding
Calb1 Calbindin-28 K ↓ 1.5* ↓ 1.5* (↓ 1.3)
Nptx2 Neuronal pentraxin 2 ↑ 2.7 n.p. ↑ 1.9*
S100a6 S100 calcium binding protein A6 (calcyclin) ↑ 1.5 ↑ 1.7 ↑ 1.9*
Channel activity
Clic1 Chloride intracellular channel 1 (↑ 1.1) ↑ 1.4* (↓ 1.1)
Enzymatic activity
Alox12b Arachidonate 12-lipoxygenase, 12R type (↓ 1.1) ↓ 1.5* (↓ 1.1)
Capn3 Calpain 3 ↓ 1.7* (↑ 1.1) (↑ 1.1)
Cyp4f15 Cytochrome P450, family 4, subfamily f, polypeptide 15 (↓ 1.2) ↓ 1.4* n.p.
Ela1 Elastase 1, pancreatic (1) ↑ 1.5* n.p.
Hs6st2 Heparan sulfate 6-O-sulfotransferase 2 ↓ 1.4* (↓ 1.2) (↓ 1.1)
Lpin2 Lipin 2 ↑ 1.5* n.p. ↑ 1.5*
P4ha1 Procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha 1 polypeptide (↑ 1.2) (↑ 1.1) ↑ 1.8*
Pctk3 PCTAIRE-motif protein kinase 3 ↑ 1.5* ↑ 1.4 (↑ 1.1)
Pip5k1b Phosphatidylinositol-4-phosphate 5-kinase, type 1 beta ↓ 1.9* ↓ 1.5* (↓ 1.2)
Prdx4 Peroxiredoxin 4 (↓ 1.2) (↓ 1.2) ↓ 1.5*
Prss23 Protease, serine, 23 (↓ 1.1) n.p. ↑ 1.7*
3930401K13Rik RIKEN cDNA 3930401K13 gene (1) (1) ↑ 1.4*
Growth factor activity
Bdnf Brain-derived neurotrophic factor ↑ 2.1 ↑ 2.2 ↑ 2.1*
Igfbp6 Insulin-like growth factor-binding protein 6 ↑ 1.7* n.p. n.p.
Inhba Inhibin beta-A (↑ 1.3) ↑ 2.9 ↑ 2.7*
Ntf3 Neurotrophin 3 ↓ 2* ↓ 2.1* (↓ 1.2)
Hormone activity
Cort Cortistatin (1) ↓ 2.5* n.p.
Grp Gastrin-releasing peptide ↑ 1.8* n.p. n.p.
Immune system
C1qc Complement component 1, q subcomponent, C chain ↑ 1.4* ↑ 1.4 n.p.
C4b Complement component 4B (Childo blood group) ↑ 1.7* ↑ 1.7* ↑ 1.4
H2-K1 Histocompatibility 2, K1, K region ↑ 1.4* n.p. n.p.
Mfge8 Milk fat globule-EGF factor 8 protein (↓ 1.3) ↓ 1.5* (↓ 1.2)
Opioid peptide activity
Penk1 Preproenkephalin 1 ↑ 3* ↑ 2.8 n.p.
Receptor activity
Gabrd Gamma-aminobutyric acid (GABA-A) receptor, subunit delta ↓ 1.6* ↓ 1.6* n.p.
Gprc5b G protein-coupled receptor, family C, group 5, member B ↑ 1.4* n.p. (↑ 1.1)
Lypd1 Ly6/Plaur domain containing 1 ↓ 1.4* ↓ 1.6* (↓ 1.3)
Signal transduction
Rgs2 Regulator of G-protein signaling 2 ↑ 1.4 ↑ 1.4 ↑ 1.6*
Rgs4 Regulator of G-protein signaling 4 ↑ 1.6 ↑ 1.6 ↑ 1.4*
Stat3 Signal transducer and activator of transcription 3 ↑ 1.4* (↑ 1.3) (↓ 1.2)
Structural molecule
Col6a1 Procollagen, type VI, alpha 1 ↑ 1.6* ↑ 2.7 n.p.
Dsp Desmoplakin ↓ 1.6* n.p. n.p.
Gfap Glial fibrillary acidic protein ↑ 2.2* ↑ 1.4 ↑ 1.4
Vim Vimentin ↑ 2* ↑ 1.7 ↑ 2.3*
Transcription factor activity
Egr1 Early growth response 1 ↑ 1.6 ↑ 1.7 ↑ 1.8*
Egr3 Early growth response 3 (↑ 1.1) ↑ 1.9 ↑ 1.5*
Sox11 SRY-box containing gene 11 ↑ 1.7 ↑ 2.5 ↑ 1.9*
Transporter activity
Slc13a3 Solute carrier family 13, member 3 ↑ 1.4* (↓ 1.3) n.p.
Slc25a18 Solute carrier family 25, member18 n.p. ↓ 1.4* n.p.
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Table 1 (continued)
Gene symbol Gene name Affy Code MPIP
Others
Trak2 Trafficking protein, kinesin-binding 2 n.p. n.p. ↑ 1.5*
Gm98 Gene model 98 (↑1.1) n.p. ↑ 1.6*
Lgals1 Lectin, galactose binding, soluble 1 ↑ 1.4* ↑ 1.5* (↑ 1.3)
Matn2 Matrilin 2 ↑ 1.5 ↑ 1.5 ↑ 1.6*
Mcl1 Myeloid cell leukemia sequence 1 ↑ 1.4* ↑ 1.5 (↑ 1.2)
Rprm Reprimo, TP53 dependent G2 arrest mediator candidate ↑ 2.3* ↑ 2.5* n.p.
Serpina3n Serine (or cysteine) proteinase inhibitor, clade A, r 3 N ↑ 1.5* ↑ 1.4* n.p.
Tex261 Testis-expressed gene 261 (1) (↓ 1.1) ↓ 1.4*
Tmepai Transmembrane, prostate androgen-induced RNA ↑ 1.4 (↑ 1.1) ↑ 1.5*
Sh2d5 SH2 domain-containing 5, mRNA (cDNA clone IMAGE:4505120) n.p. n.p. ↑ 1.5*
Lrtm2 Leucine-rich repeats and transmembrane domains 2 n.p. n.p. ↑ 1.4*
1700010I14Rik RIKEN cDNA 1700010I14 gene ↓ 2* 1 n.p.
2610042L04Rik RIKEN cDNA 2610042L04 gene ↓ 1.4* n.p. n.p.
2900052N01Rik RIKEN cDNA 2900052N01 gene n.p. n.p. ↓ 1.5*
9130213B05Rik RIKEN cDNA 9130213B05 gene (↓1.3) n.p. ↓ 1.5*
Transcribed locus (Unigene Mm.397071) n.p. n.p. ↑ 2.2*
Transcribed locus (Unigene Mm.437288) n.p. n.p. ↓ 1.5*
Transcribed locus (UniGene Mm.443644) n.p. n.p. ↓ 1.5*
Acc # Accession number, Affy Affymetrix, Code codelink, MPIP Max Planck Institute of Psychiatry, ↑ up-regulated, ↓ down-regulated, n.p. not
present/below quality threshold, asterisks: significantly regulated by Paroxetine, parentheses regulation level below fold change cutoff
Fig. 4 Validation of selected
microarray results by in situ
hybridization in vehicle- and
paroxetine-treated DBA/2Ola
mice. The mRNA signals of
Penk1 (preproenkephalin 1),
Bdnf (brain-derived neurotro-
phic factor), Gfap (glial fibril-
lary acidic protein), Vim
(vimentin), Sox11 (SRY-box
containing gene 11), Calb1
(calbindin -28 K), and Tex261
(testis expressed gene 261) in
the hippocampus are shown.
The genes were selected due to
different levels of up- or down-
regulation on the three micro-
array platforms (Affymetrix,
Codelink, MPIP; see Table 1)
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behavior in DBA/2 mice by chronic paroxetine treatment
was even more pronounced: paroxetine-treated animals
showed more entries into the brightly lit compartment,
and they spent more time in this aversive compartment.
This finding is in line with previous behavioral studies
using this antidepressant drug (Mirza et al. 2007; Hascoet
et al. 2000). Ambiguous results concerning the sensitivity
of DBA/2 mice towards the effects of antidepressants were
reported. Some studies found the DBA/2 strain to be
antidepressant-sensitive (Lucki et al. 2001; Crowley et al.
2005), whereas others did not (David et al. 2003; Cervo
et al. 2005). The underlying reasons for this discrepancy
still remain to be determined. One difference between the
present study and those reporting that the DBA/2 strain did
not respond to acute antidepressant treatment is related to
the duration of drug treatment. A 28-day treatment period
was chosen here due to the objective to identify paroxetine-
induced effects on gene expression within a time frame that
might be meaningful for the human situation.
In the microarray analysis, we identified a total of 60
genes that were significantly regulated by the paroxetine
treatment, with the highest change of transcript level for
preproenkephalin (threefold up-regulated) and inhibin beta-
A (2.7-fold up-regulated). Although the same tissue
samples were probed in three different microarray plat-
forms, none of the candidate genes reached significance on
all three of them. However, 18% of the candidates were
significantly regulated on two platforms, and a total of 47%
of the candidate genes showed comparable fold-regulations
(above the fold-change cut-off) on at least one more
platform, revealing a considerable true miss rate. Less
stringent data analysis would substantially amend the
overlap—but on the expense of a higher false discovery
rate. Of the candidate genes, 23% were present on one
platform only, and 30% were present on at least two
platforms but not comparably regulated. The latter could be
explained by platform-specific probe biases or technical
variances. Noteworthy, many of the genes differentially
regulated in our analysis were also described to be
significantly altered in a very recently published study by
Miller et al. (2008). They used a similar treatment
procedure (orally via drinking water over 21 days), the
closely related DBA/2 J mouse strain, and a SSRI
(fluoxetine). Comparing the lists of antidepressant-regulated
genes, a total of 20 candidates was found in both the
study of Miller et al (2008) and our study including
candidates like Penk1, Inhba, or neuronal pentraxin 2
(Nptx2).
For validation purposes, we have chosen seven genes
(Penk1, Bdnf, Gfap, Sox11, Vim, Calb 1, Tex261) that were
regulated between 1.4- and threefold and represent the
different platforms used. By in situ hybridization, we
Fig. 5 Colocalization of GFAP
(glial fibrillary acidic protein)
and vimentin in the hippocam-
pus of vehicle- (a) and parox-
etine- (b) treated DBA/2Ola
mice. Sections were double
stained by immunofluorescence
for GFAP (green signal) and
vimentin (red), bis-benzimide
was used as counterstain (blue
signal). Cells positive for both
signals, GFAP and Vimentin, are
marked by the circles. Individu-
al analyses of five animals per
treatment (c) revealed for each
of the paroxetine-treated mice
(black bars; grey bars: vehicle-
treated) a higher number of cells
co-expressing GFAP and
Vimentin in the subgranular
layer of the hippocampus
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confirmed that Penk1, Bdnf, Gfap, Vim, and Sox11 were up-
regulated and that expression of Calb1 and Tex261 was
decreased by paroxetine.
In Table 1, we have listed, by functional classification,
those transcripts that were significantly changed following
paroxetine treatment. When functionally classifying tran-
scripts, we observed that differentially regulated genes
could be separated into 12 main categories: calcium
binding, channel activity, enzymatic activity, growth factor
activity, hormone activity, immune system, opioid peptide
activity, receptor activity, signal transduction, structural
molecules, transcription factor activity, and transporter
activity. Genes that were not attributable to one of these
categories where included in the category entitled “others”.
As it is obvious from Table 1, antidepressant-induced
effects are consonant with known interactions including
signal transduction, ion channels, receptors, neuropeptides
and transporters as well as hormonal and immune systems.
The exact mechanisms by which the listed transactions are
regulated by paroxetine and which biochemical effects
these changes in gene activity may have, remains to be
elucidated. In the following, we will confine ourselves to a
number of observed candidates that are better understood in
the context of previous reports.
Paroxetine enhances preproenkephalin 1 (Penk1)
expression
We found the transcript of Penk1, the precursor of Met- and
Leu-enkephalin, to be threefold up-regulated following
paroxetine treatment. Enkephalins belong to the family of
endogenous opioids and are involved in, e.g., reward/
motivation (Barbano and Cador 2007) and the regulation of
the stress response (Drolet et al. 2001). An involvement
of the endogenous opioidergic system in the mediation of
several symptoms of depression has long been discussed,
and it has been shown that enkephalin catabolism inhibitors
(RB101) induce antidepressant-like effects (Roques 2000).
A recent study showed that deletion of Penk1 in mice
resulted in elevated levels of anxiety (Bilkei-Gorzo et al.
2004) and supports the idea that the anxiolytic effect of
long-term paroxetine treatment found in the present study
might be partly related to a marked increase of Penk1
expression. In seeming contrast to the present study, repeated
application of fluoxetine did not alter Penk1 expression in
male Wistar rats as measured by in situ hybridization in
different brain regions (Dziedzicka-Wasylewska et al. 2002).
The conflicting results might be explained by several
methodological differences, of which the shorter treatment
period might be the most critical factor (Boehm et al. 2006;
Shishinka et al. 2007). A recent study reports the effects of
enkephalins on behavior and BDNF expression in the
hippocampus (Zhang et al. 2006). In our study, we also
determined a robust increase in Bdnf expression in the
hippocampus of paroxetine-treated DBA/2 mice.
Paroxetine-induced effects on neurotrophic factors
Current hypotheses on causality of depression and antide-
pressant mechanisms of action include the monoamine
hypothesis built upon antidepressants pharmacology
(Hirschfeld 2000), the corticosteroid receptor hypothesis
explaining behavioral changes as sequel to defunct adapta-
tion to stressors (Holsboer 2000; de Kloet et al. 2005) and
the neurotrophic hypothesis (for review see Nestler et al.
2002). All three hypotheses are complementary to each
other. The neurotrophic hypothesis of depression and
antidepressant mechanism of action was formulated as
stressed rats showed decreased levels of hippocampal
BDNF, and antidepressants were shown to produce oppo-
site effects, thus compensating the stress-related BDNF
suppression (e.g. Nibuya et al. 1995). The finding of
opposite effects of antidepressants on stress-induced BDNF
suppression is supported by a recent study that indicated an
antidepressant-reversible up-regulation of apoptotic pro-
cesses by chronic mild stress in rats (Bergstrom et al. 2007).
Because hippocampi of depressive patients were found to
be smaller than those of controls, it was suggested that the
stress-induced decrease of BDNF accounts for structural
damage and reduced neurogenesis among these patients
(Manji and Duman 2001). Vice versa, it is proposed that
antidepressants reinstate hippocampal size and function
through elevation of BDNF and other neurotrophic factors
(see Duman and Monteggia 2006). Interestingly, an
interaction of antidepressant treatment effects and elevated
expression of neurotrophic factors is not limited to pharma-
cological manipulation. Voluntary exercise was suggested to
have antidepressant properties in animal models (Duman
et al. 2008) and mood-elevating actions in humans (Babyak
et al. 2000). A recent microarray study showed that also
voluntary exercise up-regulated several neurotrophic factors
(Hunsberger et al. 2007). Although more research is needed
to validate the neurotrophic hypothesis, we were impressed
by how many genes implicated in neurotrophic actions
were found to be regulated by paroxetine.
Among others, the transcript of BDNF was up-regulated,
while expression of neurotrophin-3 (Ntf3, NT-3) was down-
regulated. Interestingly, stress, often precipitating depressive
episodes, has been shown to display opposite effects on
BDNF and NT-3 expression in the hippocampus of rodents:
BDNF was down-regulated, while expression of NT-3 was
up-regulated (Smith 1996). The altered expression of
neurotrophins might be related to the observation that
chronic stress leads to atrophy in hippocampal CA3
neurons (McEwen 2005). These stress effects have been
suggested to be related to the development of depression
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and might be antagonized by application of various
antidepressants. As mentioned above, it has been repeatedly
shown that several antidepressants increase BDNF in
rodents and humans (see Duman and Monteggia 2006;
but also see Coppell et al. 2003). In addition, intra-
hippocampal application of BDNF, but also NT-3, has been
shown to have antidepressant-like effects on rats in the FST
and learned helplessness paradigm (Shirayama et al. 2002).
In our experiment, we found a twofold decrease of NT-3
mRNA levels in the hippocampus in animals treated
chronically with paroxetine. NT-3 levels have been reported
to be increased in the hippocampus and in the locus
coeruleus by repeated severe stress and decreased by
electroconvulsive seizures (ECS) or by long-term treatment
with desipramine or imipramine, but not with fluoxetine or
trazodone (Smith et al. 1995; Smith 1996). Karege et al.
(2005) reported a significant decrease of BDNF and NT-3
protein levels in the hippocampus of drug-free suicide
victims compared with non-suicide controls. In drug-treated
suicide victims, neurotrophin levels were not significantly
different from non-suicide controls. This observation
further indicates that both neurotrophins might be involved
in antidepressant drug activity. On the other hand, it was
found that NT-3 inhibits both FGF2-induced neurosphere
growth and bromodeoxyuridine (BrdU) incorporation in a
dose-dependent manner (Jin et al. 2005). The latter finding
would fit with our results and would suggest that the
decrease of NT-3 might be supportive for neurogenesis.
The survival and function of neurons in the central
nervous system are dependent on an ever-growing list of
factors, and besides the candidates BDNF and NT-3, we
found some additional interesting factors involved in
neurogenesis/neuronal plasticity to be regulated by antide-
pressant treatment.
Paroxetine-induced effects on glial cells—implications
for neurogenesis
In our study, the transcript level of glial fibrillary acidic
protein (GFAP), of which the protein product is almost
exclusively expressed in astrocytes, was significantly up-
regulated by chronic paroxetine application. Alterations of
GFAP expression are observed in response to a variety of
events, and an increase might be associated to gliosis,
neurodegeneration or neuroregeneration, and also neuro-
genesis. Analysis of post mortem tissue from patients with
major depression has revealed significant reductions of
GFAP protein or in GFAP/glial cell counts in various brain
regions, suggesting a decrease of glial function in this
disorder (Fatemi et al. 2004). In a study investigating male
tree shrews that were submitted to 5 weeks of psychosocial
stress, a significant decrease of both the number and somal
volume of astroglia was detected. Additionally, it was
found that 28-days treatment with fluoxetine prevented the
stress-induced numerical decrease of astrocytes. The anti-
depressant treatment had no effects on the shrinkage of
somal volume. These changes of astroglial structural
plasticity in response to stress and antidepressant treatment
support the notion that glial changes may contribute to the
pathophysiology of affective disorders as well as the
cellular activity of antidepressants (Czeh et al. 2006; Manev
et al. 2003).
Astrocytes provide structural as well as trophic support
to neurons. They also have an important role in the immune
response of the brain, in synaptic function, clearance of
cellular ions and transmitters, in neuronal metabolism, and
in neuronal migration (Allen and Barres 2005; Araque
2006; Mennerick and Zorumski 1994; Pellerin and
Magistretti 2004; Verkhratsky et al. 1998; Vernadakis
1996). More recently, astrocytes have been recognized to
also play a role as neural progenitor cells themselves in
both the developing and mature CNS (Goldman 2003; Song
et al. 2002), and to promote neurogenesis. For example,
Song et al. (2002) cultured neural progenitors from the
adult rat hippocampus with either primary cultures of
hippocampal neurons or astrocytes. They found that neural
progenitors cultured with hippocampal astrocytes were
induced to differentiate into neurons. Our observation of a
prominent up-regulation of Gfap in the paroxetine-treated
animals by microarray analysis and in situ hybridization
raises the question whether this might indicate neuro-
genesis, especially as vimentin (another intermediate
filament protein, dynamically regulated during develop-
ment) turned out to be up-regulated as well. Our double-
labeling study in brain slices, to detect GFAP and vimentin
positive cells within the dentate gyrus, showed that some of
the cells positive for GFAP also express vimentin and are
located in the subgranular zone. Moreover, the number of
those cells was twice as high in the paroxetine-treated mice.
According to the study of Garcia et al. (2004), this indicates
that the double-labeled cells of the subgranular zone are
GFAP-expressing neural progenitors and supports the
notion that increased neurogenesis occurs in hippocampi
of chronically paroxetine-treated mice.
Paroxetine-induced effects on miscellaneous genes
potentially involved in neuroplasticity
Other candidates of our list seemingly involved in neuro-
plasticity processes include the SYR-box containing gene
11 (Sox11) and the signal transducer and activator of
transcription 3 (Stat3), both of which we found to be up-
regulated by the paroxetine treatment. The transcription
factor Sox11 is known to be expressed during later stages
of neural development in areas of the brain in which
neurons undergo differentiation (Kuhlbrodt et al. 1998). In
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vitro studies suggest that Sox11 is centrally involved in
regulating events that promote neurite growth and neuron
survival (Jankowski et al. 2006). In the adult brain, Sox11
expression is weak under basal conditions but has been
found to be up-regulated after experimentally induced
seizures or nerve injury and has been linked to injury-
induced neuritogenesis (Elliott et al. 2003; Tanabe et al.
2003). So far, Sox11 has rarely been associated to
antidepressant-induced alterations in gene expression, but a
more recent study reported an up-regulation of Sox11 within
several hours following electroconvulsive shock (ECS) in the
dentate gyrus, the piriform cortex, and in the amygdala (Sun
et al. 2005). The effect of Sox11 up-regulation in the latter
two brain regions is not known. Its activation in the
subgranular layer of the dentate gyrus by ECS (Sun et al.
2005) as well as our finding supports the notion that Sox11
is contributing to antidepressant-induced neuronal plasticity.
STAT3 is known to regulate gene transcription in
response to cytokines and growth factors. It has been
shown to be activated in reactive astrocytes (Xia et al.
2002) and to be involved in 5-HT1A-receptor-mediated
neurite outgrowth (Fricker et al. 2005). Ng et al. (2006)
identified STAT3 as an essential component of neurotrophin
signaling and functions, i.e., inhibition of STAT3 expression
decreased BDNF-promoted neurite outgrowth in primary
hippocampal neurons. Furthermore, it was suggested that
neurotrophin-induced increase in STAT3 activation under-
lies several downstream functions of neurotrophin signaling.
Sleep deprivation, which has short-term antidepressant
effects in human patients, affects a number of genes in the
cortex of rats, among which mRNA levels of STAT3 as well
as BDNF and TrkB were found to be up-regulated (Cirelli
and Tononi 2000). Additionally, they also report an
enhanced transcript level of nerve growth factor-inducible
protein A (NGFI-A).
NGFI-A (alias Egr1, zif268, krox24, ZENK) has been
shown to be up-regulated following chronic treatment with
a variety of different antidepressants (Bjartmar et al. 2000)
and is another candidate on our list of genes regulated by
chronic paroxetine application. Alterations in NGFI-A
expression have been observed in different brain regions and
seem to be responsive to a variety of stimuli (e.g., Thompson
and Rosen 2006). This factor has been associated to
serotonin-induced DNA demethylation, and it is hypothe-
sized that NGFI-A contributes to epigenetic programming of
glucocorticoid receptor expression (Weaver et al. 2007).
Conclusion
This study explores paroxetine-induced hippocampal gene
expression in mice that exhibit antidepressant-like behavioral
changes according to three independent tests. We used three
different microarray platforms and confirmed drug-induced
changes in gene activity by in situ hybridization. Within the
limitations of the available technology, we conclude that
paroxetine exerts a number of effects upon transcripts
implicated in causality and treatment of depression. Many of
the paroxetine-regulated genes are currently linked to neuro-
nal plasticity, and the effects seem to occur via different
mechanisms. Intriguingly, paroxetine seems to interfere not
only with neurons but also with glial cells indicating an
increase in progenitor cells and other factors necessary for
neuronal differentiation. The many changes in neurotrophic
factors, receptor constituents, and transcription factors may
also promote neuroplasticity in and between existing neurons.
We are aware that on this level of investigation, the
given interpretations are speculative. Nevertheless, studies
as the current one will help us to gain insight into the
mechanisms of action of current antidepressants, disentangle
the effects which contribute to the resolution of depressive
symptomatology, and ultimately might lead us to those genes
that are causally involved in depression.
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